Systemic mastocytosis and bone involvement in a cohort of 75 patients
Autor: | C De Gennes, Felipe Suarez, N. Assous, Jérôme Launay, Frédéric Féger, P. Dubreuil, Camille Francès, Danielle Canioni, Olivier Lortholary, Olivier Hermine, Fanny Lanternier, Michel Arock, Sylvie Fraitag, Clément Roux, Fabienne Palmerini, Stéphane Barete, B. Billemont, C. Grandpeix |
---|---|
Přispěvatelé: | Slama, Catherine, Cytokines, hématopoïèse et réponse immune (CHRI), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Paris 5 (UPD5) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Centre National de la Recherche Scientifique (CNRS) |
Jazyk: | angličtina |
Rok vydání: | 2010 |
Předmět: |
musculoskeletal diseases
Adult Male medicine.medical_specialty Bone density Adolescent medicine.medical_treatment Immunology Osteoporosis Urology Lumbar vertebrae General Biochemistry Genetics and Molecular Biology 03 medical and health sciences Osteosclerosis Young Adult 0302 clinical medicine Rheumatology Mastocytosis Systemic Bone Density Internal medicine medicine Immunology and Allergy Humans ComputingMilieux_MISCELLANEOUS Aged 030203 arthritis & rheumatology Bone mineral Aged 80 and over Lumbar Vertebrae Bone Density Conservation Agents Diphosphonates business.industry Bisphosphonate Middle Aged medicine.disease 3. Good health Surgery Osteopenia medicine.anatomical_structure 030220 oncology & carcinogenesis Female business Follow-Up Studies |
Zdroj: | Annals of the Rheumatic Diseases Annals of the Rheumatic Diseases, BMJ Publishing Group, 2010, 69, pp.1838-1841 |
ISSN: | 0003-4967 1468-2060 |
Popis: | Objectives To investigate bone involvement in a large cohort of systemic mastocytosis (SM) patients, and evaluate the efficacy of bisphosphonate therapy. Patients and Methods From 2000 to 2004, 75 patients with SM according to WHO criteria underwent skeletal x-rays and bone mineral density (BMD) assessment. Sequential BMD assessments were performed in nine patients treated with bisphosphonate (mean follow-up 65 months). Results 37 patients (49%) had bone involvement according to both x-rays and BMD evaluations: osteoporosis (23 patients, 31%, mean lumbar spine T score: −3 SD), with vertebral fracture (13 patients, 17%), axial skeleton osteosclerosis (six patients, 8%), mixed patterns (three patients), osteopenia with pre-existing fractures (four patients) and focal osteolytic lesion (one patient). Blood count abnormalities were associated with osteosclerosis (p=0.005). In nine patients with osteoporosis and bisphosphonate therapy, mean lumbar spine BMD increased from 0.83 to 0.92 g/cm 2 (+11.1%; ie, +2.05% per year) without recurrence of vertebral fracture. Conclusion Half of adult patients with SM have bone involvement. Osteoporosis is the most prevalent bone manifestation in SM (31%). Bisphosphonate therapy seems efficient to improve lumbar spine BMD during SM-related osteoporosis. Spine x-ray and BMD should be performed in all SM patients to detect those who may benefit from anti-osteoporotic therapy. |
Databáze: | OpenAIRE |
Externí odkaz: |